Pharmaceutical products | Tenderlake

Pharmaceutical products

Contract Value:
-
Notice Type:
Contract Notice
Published Date:
10 March 2023
Closing Date:
28 March 2025
Location(s):
DE DEUTSCHLAND (DE Germany/DEUTSCHLAND)
Description:
Contracts are being offered for various pharmaceutical products through an open-house procedure, allowing interested companies to join and conclude discount agreements for specific active ingredients until 31.05.2025.
Various open house contracts 2023

Open house contracts for various active ingredients until 31.05.2025.

Agalsidase beta, ATC-Code: A16AB04

The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a

Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.

Biperiden, ATC-Code: N04AA02

The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a

Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.

Formoterol-Aclidiniumbromid, ATC-Code: R03AL05

The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a

Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.05.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.

Download full details as .pdf
The Buyer:
AOK Bremen/Bremerhaven
CPV Code(s):
33600000 - Pharmaceutical products